DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Wolfram syndrome 2 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleWolfram syndrome 2 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for wolfram syndrome 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ubiquitin conjugating enzyme E2 D3 (UBE2D3) — UBE2D3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5EGG · 1.76 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Wolfram syndrome is a rare genetic disorder characterised by juvenile-onset diabetes mellitus, diabetes insipidus, optic nerve atrophy, hearing loss, and neurodegeneration. There are currently no effective treatments that can delay or reverse progression of the syndrome. The prognosis is poor, and many patients die prematurely with severe neurological disabilities. Clinical heterogeneity has been reported both within and between families with WFS1 mutations. In three cases with homozygous WFS1 mutations, one patient presented with insulin-dependent diabetes mellitus positive for pancreatic autoantibodies and had a ketoacidotic attack; a second presented initially with optic atrophy and had behavioural and psychiatric problems at an early age; a third had early-onset insulin-dependent diabetes with multiple anomalies and congenital hypothyroidism. Many of these features had not been reported previously in Wolfram syndrome.
The natural history and etiology have been described, and recommendations for diagnosis and clinical management are available. Supportive care can help relieve suffering and improve quality of life. However, no treatment currently exists to delay, halt, or reverse progression of Wolfram syndrome. The urgency for developing novel treatments is raised repeatedly in the literature, but no drug intervention is tested or reported in these abstracts.
What is still missing is any evidence from a clinical trial of a drug that alters the course of the disease. No candidate agent has shown a survival benefit, a delay in neurodegeneration, or an improvement in any objective endpoint in a controlled study. The field lacks funded trials, validated biomarkers for patient stratification, and a clear regulatory pathway for a disorder where the characteristic features may present at different times, making trial design difficult.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Diabetes Reports · 2016 · 304 citations · open access
Wolfram Syndrome: Diagnosis, Management, and Treatment
AbstractWolfram syndrome is a rare genetic disorder characterized by juvenile-onset diabetes mellitus, diabetes insipidus, optic nerve atrophy, hearing loss, and neurodegeneration. Although there are currently no effective treatments that can delay or reverse the progression of Wolfram syndrome, the use of careful clinical monitoring and supportive care can help relieve the suffering of patients and improve their quality of life. The prognosis of this syndrome is currently poor, and many patients die prematurely with severe neurological disabilities, raising the urgency for developing novel treatments for Wolfram syndrome. In this article, we describe natural history and etiology, provide recommendations for diagnosis and clinical management, and introduce new treatments for Wolfram syndrome.
Trends in Pharmacological Sciences · 2019 · 57 citations · open access
Current Landscape of Treatments for Wolfram Syndrome
AbstractWolfram syndrome is a rare genetic spectrum disorder characterized by insulin-dependent diabetes mellitus, optic nerve atrophy, and progressive neurodegeneration, and ranges from mild to severe clinical symptoms. There is currently no treatment to delay, halt, or reverse the progression of Wolfram syndrome, raising the urgency for innovative therapeutics for this disease. Here, we summarize our vision for developing novel treatment strategies and achieving a cure for Wolfram-syndrome-spectrum disorder.
Journal of Pediatric Endocrinology and Metabolism · 2014 · 7 citations
Three cases of Wolfram syndrome with different clinical aspects
AbstractBACKGROUND: Wolfram syndrome is an autosomal recessive disorder caused by mutations in the WFS1 gene. Clinical heterogeneity has been reported both within and between families with WFS1 mutations. SUBJECTS: The first case was diagnosed with insulin-dependent diabetes mellitus with positive for pancreatic autoantibodies and had a ketoacidotic attack in the follow-up period. The second case presented initially with optic atrophy and was diagnosed with behavioral and psychiatric problems at an early age. The third case had early onset insulin-dependent diabetes with multiple anomalies and congenital hypothyroidism. Many of these features have not been reported previously in patients with Wolfram syndrome. In all three patients homozygous mutations in WFS1 were identified. CONCLUSION: Wolfram syndrome is a disease where the characteristic features may present at different times. A diagnosis of Wolfram syndrome should therefore be considered even in the absence of the full spectrum of clinical features.
[Advances in diagnosis and treatment of Wolfram syndrome and related molecular mechanism].
AbstractWolfram syndrome is a rare genetic spectrum disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, and deafness, accompanied by other variable clinical manifestations. At present, the prognosis of this syndrome is very poor, the specific molecular mechanism is not clear, effective treatments are lacking to delay, prevent or reverse the development of Wolfram syndrome, and many patients die prematurely due to severe neurological dysfunction. This increases the urgency of the research on the pathogenic molecular mechanism related to Wolfram syndrome and the development of new therapies. This article summarizes the research progress on the pathogenic molecular mechanism and treatment status of Wolfram syndrome, in order to provide reference for the further mechanism research, prevention and treatment of Wolfram syndrome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
